|A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response||
||540||All||18 Years to 70 Years (Adult, Senior)||NCT00758043||VX08-950-111
|October 2008||June 2010||July 2010||September 23, 2008||October 30, 2013||July 21, 2011||
|2||NCT03268317||Not yet recruiting||Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs||
||100||All||Child, Adult, Senior||NCT03268317||NAEIPWCHCTBDAAD||January 2018||January 2019||January 2020||August 31, 2017||August 31, 2017|
|3||NCT02113631||Completed||Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir||
||50||All||18 Years and older (Adult, Senior)||NCT02113631||IRB #: 11064-H40||September 2011||April 2013||April 2013||April 14, 2014||March 15, 2017||
† Study has passed its completion date and status has not been verified in more than two years.